drugset / Trial / NCT03601897
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with paclitaxel designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in patients with advanced or metastatic solid tumors.
Timeline
- Start
- 2018-10-25
- Primary completion
- 2022-05-23
- Completion
- 2022-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Subject | Rebastinib | Small molecule | 50 mg | Oral |
| Subject | Rebastinib | Small molecule | 100 mg | Oral |
Indications
No indication recorded.